Opdivo | BioChronicles

Warning: Creating default object from empty value in /customers/4/c/6/biochronicles.net/httpd.www/wp-content/plugins/widgetize-pages-light/include/otw_labels/otw_sbm_grid_manager_object.labels.php on line 2 Warning: Creating default object from empty value in /customers/4/c/6/biochronicles.net/httpd.www/wp-content/plugins/widgetize-pages-light/include/otw_labels/otw_sbm_shortcode_object.labels.php on line 2 Warning: Creating default object from empty value in /customers/4/c/6/biochronicles.net/httpd.www/wp-content/plugins/widgetize-pages-light/include/otw_labels/otw_sbm_factory_object.labels.php on line 2 Opdivo | BioChronicles

IL NOBEL 2018 E LE PROSPETTIVE DELL’IMMUNOTERAPIA TUMORALE

I prof. Allison e Honjo da anni studiano l'immunoterapia per combattere i tumori. Il trucco è togliere i freni che inibiscono i linfociti.

Dic 05, 2018 / 0 comment / Biochronicles / Tags: ACT, Allison, Coley, Honjo, immunoterapia, linfociti, Opdivo, premio Nobel, Yervoy

Showing the single result

TOP

Settings

Shopping Bag

IL NOBEL 2018 E LE PROSPETTIVE DELL’IMMUNOTERAPIA TUMORALE

Newsletter